DE60122286D1 - Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen - Google Patents

Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen

Info

Publication number
DE60122286D1
DE60122286D1 DE60122286T DE60122286T DE60122286D1 DE 60122286 D1 DE60122286 D1 DE 60122286D1 DE 60122286 T DE60122286 T DE 60122286T DE 60122286 T DE60122286 T DE 60122286T DE 60122286 D1 DE60122286 D1 DE 60122286D1
Authority
DE
Germany
Prior art keywords
antibody
based fusion
fusion proteins
increasing
time
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60122286T
Other languages
English (en)
Other versions
DE60122286T2 (de
Inventor
D Gillies
Christa Burger
Ming Lo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of DE60122286D1 publication Critical patent/DE60122286D1/de
Application granted granted Critical
Publication of DE60122286T2 publication Critical patent/DE60122286T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60122286T 2000-02-11 2001-02-09 Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen Expired - Lifetime DE60122286T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18176800P 2000-02-11 2000-02-11
US181768P 2000-02-11
PCT/US2001/004455 WO2001058957A2 (en) 2000-02-11 2001-02-09 Enhancing the circulating half-life of antibody-based fusion proteins

Publications (2)

Publication Number Publication Date
DE60122286D1 true DE60122286D1 (de) 2006-09-28
DE60122286T2 DE60122286T2 (de) 2007-08-02

Family

ID=22665708

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60122286T Expired - Lifetime DE60122286T2 (de) 2000-02-11 2001-02-09 Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen

Country Status (16)

Country Link
US (3) US7091321B2 (de)
EP (1) EP1252192B1 (de)
JP (2) JP5179689B2 (de)
CN (1) CN1406249B (de)
AT (1) ATE336514T1 (de)
AU (1) AU4314801A (de)
CA (1) CA2399832C (de)
CY (1) CY1105725T1 (de)
DE (1) DE60122286T2 (de)
DK (1) DK1252192T3 (de)
ES (1) ES2269366T3 (de)
HU (1) HUP0204475A2 (de)
MX (1) MXPA02007733A (de)
NO (1) NO20023774D0 (de)
PT (1) PT1252192E (de)
WO (1) WO2001058957A2 (de)

Families Citing this family (263)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2221717T3 (es) 1997-12-08 2005-01-01 Emd Lexigen Research Center Corp. Proteinas de fusion heterodimeras utiles para inmunoterapia dirigida e inmunoestimulacion general.
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
US7387772B1 (en) * 1999-06-22 2008-06-17 Immunimedics, Inc. Chimeric, human and humanized anti-CSAP monoclonal antibodies
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
KR20060067983A (ko) 1999-01-15 2006-06-20 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
CA2372400C (en) * 1999-05-19 2010-04-27 Lexigen Pharmaceuticals Corp. Expression and export of interferon-alpha proteins as fc fusion proteins
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US20050202538A1 (en) * 1999-11-12 2005-09-15 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
ATE336514T1 (de) 2000-02-11 2006-09-15 Merck Patent Gmbh Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen
RU2272644C2 (ru) * 2000-06-29 2006-03-27 Мерк Патент Гмбх Усиление иммунной реакции, медиатором которой является слитый протеин антитело-цитокин, при помощи комбинированного лечения агентами, увеличивающими поглощение иммуноцитокина
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
ATE489395T1 (de) 2000-12-12 2010-12-15 Medimmune Llc Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung
EP1366067B1 (de) 2001-03-07 2012-09-26 Merck Patent GmbH Verfahren zur expression von proteinen mit einer hybrid-isotyp-antikörpereinheit
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
AU2002308562B2 (en) 2001-05-03 2008-01-24 Merck Patent Gmbh Recombinant tumor specific antibody and use thereof
EP1454138B1 (de) 2001-12-04 2012-01-18 Merck Patent GmbH Immunocytokine mit modulierter selektivität
AU2003209755B2 (en) * 2002-02-06 2007-11-22 Ares Trading S.A. Tumor necrosis factor combined with interferon in demyelinating diseases
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
AU2003265866A1 (en) * 2002-09-03 2004-03-29 Vit Lauermann Targeted release
US20060020396A1 (en) * 2002-09-09 2006-01-26 Rene Gantier Rational directed protein evolution using two-dimensional rational mutagenesis scanning
US7217798B2 (en) 2003-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of Fc-fusion protein serum half-lives by mutagenesis
US7365168B2 (en) 2002-10-15 2008-04-29 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
PL211180B1 (pl) 2002-12-17 2012-04-30 Merck Patent Gmbh Białko fuzyjne typu przeciwciało-IL2, wektor zawierający sekwencję kwasów nukleinowych kodujących takie białko, kompozycja farmaceutyczna zawierająca takie białko fuzyjne oraz jego zastosowania do wytwarzania leków
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
ES2333598T5 (es) 2003-05-06 2013-09-04 Biogen Idec Hemophilia Inc Proteinas quimericas del factor de coagulacion fc para tratar la hemofilia.
US20050069521A1 (en) * 2003-08-28 2005-03-31 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of interleukin-2 proteins
DE602004013372T2 (de) * 2003-12-30 2009-07-02 Merck Patent Gmbh Il-7-fusionsproteine mit antikörperportionen, deren herstellung und deren verwendung
JP2008504008A (ja) * 2003-12-31 2008-02-14 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 改良された薬物動態を有するＦｃ−エリスロポエチン融合タンパク質
EP1702069A2 (de) 2004-01-05 2006-09-20 EMD Lexigen Research Center Corp. Auf onkofötales fibronectin gerichtetes interleukin-12
DE602005016773D1 (de) * 2004-01-22 2009-11-05 Merck Patent Gmbh Antikrebs-antikörper mit reduzierter komplementfixierung
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
EP1776384B1 (de) 2004-08-04 2013-06-05 Mentrik Biotech, LLC Variante fc-regionen
WO2006023420A2 (en) * 2004-08-16 2006-03-02 Medimmune, Inc. Integrin antagonists with enhanced antibody dependent cell-mediated cytotoxicity activity
KR20070085886A (ko) * 2004-12-09 2007-08-27 메르크 파텐트 게엠베하 감소된 면역원성의 ｉｌ-7 변이체
CN100429233C (zh) * 2005-02-03 2008-10-29 上海长海医院 一种重组融合蛋白及其制备方法及用途
AU2006214121B9 (en) 2005-02-15 2013-02-14 Duke University Anti-CD19 antibodies and uses in oncology
US8008443B2 (en) * 2005-04-26 2011-08-30 Medimmune, Llc Modulation of antibody effector function by hinge domain engineering
JP5047947B2 (ja) 2005-05-05 2012-10-10 デューク ユニバーシティ 自己免疫疾患のための抗ｃｄ１９抗体治療
CA2614181A1 (en) * 2005-07-01 2007-01-11 Medimmune, Inc. An integrated approach for generating multidomain protein therapeutics
US20070104689A1 (en) * 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
KR20080073293A (ko) 2005-10-14 2008-08-08 메디뮨 엘엘씨 항체 라이브러리의 세포 디스플레이
WO2007053577A2 (en) * 2005-10-31 2007-05-10 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
EP2270050B1 (de) 2005-12-30 2013-06-05 Merck Patent GmbH Anti-C19 Antikörper mit reduzierter Immunogenizität
WO2007076933A1 (en) * 2005-12-30 2007-07-12 Merck Patent Gmbh Interleukin-12p40 variants with improved stability
JP2009525986A (ja) * 2006-02-03 2009-07-16 メディミューン，エルエルシー タンパク質製剤
EP1816201A1 (de) 2006-02-06 2007-08-08 CSL Behring GmbH Modifizierter Koagulationsfaktor VIIa mit verbesserter 'half-life'-Stabiltät
EP2540741A1 (de) 2006-03-06 2013-01-02 Aeres Biomedical Limited Humanisierte Anti-CD22-Antikörper und ihre Verwendung bei der Behandlung von Krebs, Transplantationen und Autoimmunerkrankungen
JP5368301B2 (ja) 2006-06-22 2013-12-18 ノボ・ノルデイスク・エー／エス 可溶性ヘテロ二量体レセプター及びその使用
DE602006016765D1 (de) * 2006-06-30 2010-10-21 Conaris Res Inst Ag Verbesserte sgp 130Fc Dimere
EP2038417A2 (de) * 2006-07-06 2009-03-25 Merck Patent GmbH Zusammensetzungen und verfahren zur verstärkung der wirksamkeit von il-2-vermittelten immunreaktionen
EP1878747A1 (de) 2006-07-11 2008-01-16 greenovation Biotech GmbH Glyco-hergestellte Antikörper
TW200817438A (en) * 2006-08-17 2008-04-16 Hoffmann La Roche A conjugate of an antibody against CCR5 and an antifusogenic peptide
MX2009002522A (es) * 2006-09-08 2009-06-19 Genentech Inc Antagonistas de wnt y su uso en el diagnóstico y tratamiento de trastornos mediados por wnt.
WO2008077616A1 (en) 2006-12-22 2008-07-03 Csl Behring Gmbh Modified coagulation factors with prolonged in vivo half-life
CN101861168B (zh) 2007-05-07 2014-07-02 米迪缪尼有限公司 抗-icos抗体及其在治疗肿瘤、移植和自身免疫病中的应用
CN105175553B (zh) * 2007-05-30 2019-11-22 浦项工科大学校产学协力团 免疫球蛋白融合蛋白
EP3173484B1 (de) * 2007-05-30 2018-09-26 Postech Academy-Industry- Foundation Immunglobulinfusionsproteine
EP1997830A1 (de) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV-spezifische Bindemoleküle und Mittel zu ihrer Herstellung
WO2009006520A1 (en) * 2007-07-03 2009-01-08 Medimmune, Llc Hinge domain engineering
AR067537A1 (es) * 2007-07-17 2009-10-14 Hoffmann La Roche Purificacion de polipeptidos pegilados
CL2008002054A1 (es) * 2007-07-17 2009-05-29 Hoffmann La Roche Metodo para la regeneracion de una columna de cromatografia de intercambio cationico despues de la elusion de eritropoyetina monopeguilada y metodo para obtener una eritropoyetina monopeguilada, incorporando el metodo de regeneracion de la columna de intercambio cationico.
AR067584A1 (es) 2007-07-20 2009-10-14 Hoffmann La Roche Un conjugado de un anticuerpo contra la cd4 y peptidos antifusogenicos
WO2009018386A1 (en) 2007-07-31 2009-02-05 Medimmune, Llc Multispecific epitope binding proteins and uses thereof
EP2245064B1 (de) 2007-12-21 2014-07-23 Medimmune Limited BINDUNGSELEMENTE FÜR INTERLEUKIN-4-REZEPTOR ALPHA (IL-4Ralpha)
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
BRPI0907046A2 (pt) 2008-01-18 2015-07-28 Medimmune Llc Anticorpo de cisteína engenheirada, ácido nucleico isolado, vetor, célula hospedeira, conjugado de anticorpo, composição farmacêutica, métodos de detecção de câncer, doenças ou distúrbios autoimunes, inflamatórios ou infecciosos em um indivíduo e de inibição de proliferação de uma célula alvo
WO2009098596A2 (en) * 2008-02-05 2009-08-13 Zymeworks Inc. Methods for determining correlated residues in a protein or other biopolymer using molecular dynamics
WO2009128931A1 (en) * 2008-04-18 2009-10-22 Abbott Laboratories In vitro estimation of in vivo half-life binding proteins
JP5792621B2 (ja) 2008-09-26 2015-10-14 オンコメッド ファーマシューティカルズ インコーポレイテッド ｆｒｉｚｚｌｅｄ結合剤およびその使用
US20100082438A1 (en) * 2008-10-01 2010-04-01 Ronnie Jack Garmon Methods and systems for customer performance scoring
CA2743469C (en) 2008-11-12 2019-01-15 Medimmune, Llc Antibody formulation
WO2010068722A1 (en) 2008-12-12 2010-06-17 Medimmune, Llc Crystals and structure of a human igg fc variant with enhanced fcrn binding
CA2749539C (en) 2009-01-21 2022-07-19 Amgen Inc. Compositions and methods comprising interleukin-2 mutants for treating inflammatory and autoimmune diseases
EA201171259A1 (ru) 2009-04-22 2012-05-30 Мерк Патент Гмбх Антительные гибридные белки с модифицированными сайтами связывания fcrn
WO2011005481A1 (en) 2009-06-22 2011-01-13 Medimmune, Llc ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION
US8221753B2 (en) * 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
CN102711809B (zh) 2009-08-17 2015-09-30 特雷康制药公司 使用抗-内皮因子抗体和抗-vegf剂联合治疗癌症
EP2470559B1 (de) 2009-08-24 2017-03-22 Amunix Operating Inc. Gerinnungsfaktor-ix-zusammensetzungen sowie verfahren zu ihrer herstellung und verwendung
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
TR201804897T4 (tr) 2009-10-07 2018-06-21 Macrogenics Inc Fukosi̇lasyon ölçüsünün deği̇şi̇mleri̇nden dolayi geli̇şmi̇ş efektör i̇şlevi̇ sergi̇leyen fc bölgesi̇ni̇ i̇çeren poli̇pepti̇tler ve bunlarin kullanimlarina yöneli̇k yöntemler
JP2013512674A (ja) * 2009-12-02 2013-04-18 アクセルロン ファーマ， インコーポレイテッド Ｆｃ融合タンパク質の血清半減期を増加させるための組成物および方法
MX336830B (es) 2009-12-06 2016-02-03 Biogen Hemophilia Inc Polipeptidos hibridos y quimericos del factor viii-fc, y metodos de uso de los mismos.
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
SG10201503351RA (en) 2010-01-19 2015-06-29 Harvard College Engineered Opsonin for Pathogen Detection and Treatment
CN105001334A (zh) 2010-02-10 2015-10-28 伊缪诺金公司 Cd20抗体及其用途
MX347515B (es) 2010-04-01 2017-04-28 Oncomed Pharmaceuticals Inc * Agentes que se unen al receptor encrespado y usos de los mismos.
WO2012006623A1 (en) 2010-07-09 2012-01-12 Biogen Idec Hemophilia Inc. Systems for factor viii processing and methods thereof
EA037095B1 (ru) 2010-07-09 2021-02-05 Биовератив Терапьютикс Инк. Способ лечения гемофилии в и эпизодов кровотечения
EP2603526A1 (de) 2010-08-13 2013-06-19 Medimmune Limited Monomere polypeptide mit abweichenden fc-regionen und verwendungsverfahren
WO2012022734A2 (en) 2010-08-16 2012-02-23 Medimmune Limited Anti-icam-1 antibodies and methods of use
CA2808748C (en) 2010-09-14 2018-09-11 Roberto Falkenstein Method for purifying pegylated erythropoietin
HUE041335T2 (hu) 2011-03-29 2019-05-28 Roche Glycart Ag Antitest FC-variánsok
PL2697257T3 (pl) 2011-04-13 2017-04-28 Bristol-Myers Squibb Company Białka fuzyjne fc o nowatorskim układzie lub zawierające nowatorskie łączniki
CN106432506A (zh) 2011-05-24 2017-02-22 泽恩格尼亚股份有限公司 多价和单价多特异性复合物及其用途
EP2718328A4 (de) 2011-06-08 2014-12-24 Acceleron Pharma Inc Zusammensetzungen und verfahren zur erhöhung der halbwertszeit von serum
EP2537933A1 (de) 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) Auf IL-15- und IL-15Ralpha-Sushi-Domäne basierende Immunozytokine
EP3626739A1 (de) 2011-06-24 2020-03-25 Stephen D. Gillies Leichtkettige immunglobulinfusionsproteine und verfahren zur verwendung davon
CN103930440A (zh) 2011-07-01 2014-07-16 拜耳知识产权有限责任公司 松弛素融合多肽及其用途
WO2013007563A1 (en) 2011-07-08 2013-01-17 Bayer Intellectual Property Gmbh Fusion proteins releasing relaxin and uses thereof
EA029045B1 (ru) 2011-07-08 2018-02-28 Байоджен Хемофилия Инк. Химерные и гибридные полипептиды фактора viii и способы их применения
WO2013016454A1 (en) 2011-07-25 2013-01-31 Biogen Idec Hemophilia Inc. Assays to monitor bleeding disorders
EP2760471B9 (de) 2011-09-30 2017-07-19 Dana-Farber Cancer Institute, Inc. Therapeutische peptide
SG11201401518TA (en) 2011-10-28 2014-05-29 Teva Pharmaceuticals Australia Pty Ltd Polypeptide constructs and uses thereof
JP2014533249A (ja) 2011-11-07 2014-12-11 メディミューン，エルエルシー 多重特異性を持つ多価結合タンパク質およびその使用
JP2015502397A (ja) 2011-12-23 2015-01-22 ファイザー・インク 部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用
LT2802668T (lt) 2012-01-12 2018-11-26 Bioverativ Therapeutics Inc. Imunogeninio atsako prieš faktorių viii individuose, kuriems skiriama faktoriaus viii terapija, sumažinimas
WO2013123457A1 (en) 2012-02-15 2013-08-22 Biogen Idec Ma Inc. Recombinant factor viii proteins
RS63870B1 (sr) 2012-02-15 2023-01-31 Bioverativ Therapeutics Inc Sastavi faktora viii i postupci za pravljenje i upotrebu istih
ES2800426T3 (es) * 2012-03-03 2020-12-30 Immungene Inc Moléculas de fusión anticuerpos-mutante de interferón modificadas
AU2013255542C1 (en) 2012-04-30 2017-06-22 Biocon Limited Targeted/immunomodulatory fusion proteins and methods for making same
PE20150361A1 (es) 2012-07-13 2015-03-14 Roche Glycart Ag Anticuerpos biespecificos anti-vegf/anti-ang-2 y su utilizacion en el tratamiento de enfermedades vasculares oculares
SG11201500489YA (en) 2012-07-25 2015-02-27 Kolltan Pharmaceuticals Inc Anti-kit antibodies and uses thereof
RU2015106812A (ru) 2012-08-02 2016-09-27 Ф.Хоффманн-Ля Рош Аг Способ получения мономерных и мультимерных молекул и их применение
UA115789C2 (uk) 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
WO2014052490A1 (en) 2012-09-25 2014-04-03 Biogen Idec Ma Inc. Methods of using fix polypeptides
US10391152B2 (en) 2012-10-18 2019-08-27 Bioverativ Therapeutics Inc. Methods of using a fixed dose of a clotting factor
EP2911691B1 (de) 2012-10-23 2018-10-10 OncoMed Pharmaceuticals, Inc. Verfahren zur behandlung von neuroendokrinen tumoren mit wnt-pad-bindemitteln
US20150266944A1 (en) 2012-10-30 2015-09-24 Biogen Idec Ma Inc. Methods of Using FVIII Polypeptide
WO2014121196A1 (en) 2013-02-04 2014-08-07 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a wnt pathway inhibitor
EP3299378B1 (de) 2013-02-12 2019-07-31 Bristol-Myers Squibb Company Rückfaltungsverfahren für protein mit hohem ph-wert
EP3744728A1 (de) 2013-02-12 2020-12-02 Bristol-Myers Squibb Company Tangentialstromfiltration auf der basis von proteinrückfaltungsverfahren
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
US10745483B2 (en) 2013-03-15 2020-08-18 Dana-Farber Cancer Institute, Inc. Therapeutic peptides
JP6330026B2 (ja) 2013-03-15 2018-05-23 バイオベラティブ セラピューティクス インコーポレイテッド 第ｖｉｉｉ因子ポリペプチド製剤
CA2904357C (en) 2013-03-15 2020-09-22 Intrinsic Lifesciences Llc Anti-hepcidin antibodies and uses thereof
TWI683666B (zh) 2013-03-15 2020-02-01 美商百歐維拉提夫治療公司 因子ｉｘ多肽調配物
EP3424530A1 (de) 2013-03-15 2019-01-09 Zyngenia, Inc. Multivalente und monovalente multispezifische komplexe und deren verwendungen
EP2986312B1 (de) 2013-04-19 2021-12-15 Cytune Pharma Aus cytokinen abgeleitete behandlung mit reduziertem vaskulärem permeabilitätssyndrom
PT2992013T (pt) 2013-04-29 2020-03-05 Teva Pharmaceuticals Australia Pty Ltd Anticorpos anti-cd38 e fusões a interferão alfa-2b atenuado
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
CA2913155A1 (en) 2013-05-21 2014-11-27 President And Fellows Of Harvard College Engineered heme-binding compositions and uses thereof
TWI667255B (zh) 2013-08-14 2019-08-01 美商生物化學醫療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
ES2837392T3 (es) 2013-10-02 2021-06-30 Medimmune Llc Anticuerpos anti-influenza A neutralizantes y usos de los mismos
WO2015085276A1 (en) 2013-12-06 2015-06-11 Biogen Idec Ma Inc. Population pharmacokinetics tools and uses thereof
BR112016012358A2 (pt) 2013-12-06 2017-09-26 Dana Farber Cancer Inst Inc peptídios terapêuticos
DE202014010499U1 (de) 2013-12-17 2015-10-20 Kymab Limited Targeting von humaner PCSK9 zur Cholesterinbehandlung
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
EP3083658B1 (de) 2013-12-18 2019-05-08 President and Fellows of Harvard College Detektion gram-positiver bakterien mit crp
EA035324B1 (ru) 2013-12-24 2020-05-28 Ардженкс Бвба АНТАГОНИСТЫ НЕОНАТАЛЬНЫХ Fc-РЕЦЕПТОРОВ (FCRN) И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
MX2016010067A (es) 2014-02-10 2016-10-07 Merck Patent Gmbh INHIBICION DIRIGIDA DEL FACTOR DE CRECIMIENTO TRANSFORMADOR ß (TGF ß).
EP2915569A1 (de) 2014-03-03 2015-09-09 Cytune Pharma Reinigungsverfahren für Il-15/Il-15Ralpha-basierte Konjugate
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US10279021B2 (en) 2014-03-14 2019-05-07 Dana-Faber Cancer Institute, Inc. Vaccine compositions and methods for restoring NKG2D pathway function against cancers
KR102385372B1 (ko) 2014-03-24 2022-04-11 바이오버라티브 테라퓨틱스 인크. 동결건조된 ix 인자 제형
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
EA037006B1 (ru) 2014-06-06 2021-01-26 Бристол-Майерс Сквибб Компани Антитела к индуцируемому глюкокортикоидами рецептору фактора некроза опухолей (gitr) и их применения
WO2016023916A1 (en) 2014-08-12 2016-02-18 Kymab Limited Treatment of disease using ligand binding to targets of interest
US10323088B2 (en) 2014-09-22 2019-06-18 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
CA2965414C (en) 2014-10-29 2024-01-09 Teva Pharmaceuticals Australia Pty Ltd Interferon .alpha.2.beta. variants
US20160130324A1 (en) * 2014-10-31 2016-05-12 Shire Human Genetic Therapies, Inc. C1 Inhibitor Fusion Proteins and Uses Thereof
WO2016071701A1 (en) 2014-11-07 2016-05-12 Kymab Limited Treatment of disease using ligand binding to targets of interest
US9926375B2 (en) 2014-11-12 2018-03-27 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
JP2017537084A (ja) 2014-11-12 2017-12-14 トラコン ファーマシューティカルズ、インコーポレイテッド 抗エンドグリン抗体及びその用途
CN107250157B (zh) 2014-11-21 2021-06-29 百时美施贵宝公司 包含修饰的重链恒定区的抗体
ME03806B (de) 2014-11-21 2021-04-20 Bristol Myers Squibb Co Antikörper gegen cd73 und verwendungen davon
MA41116A (fr) 2014-12-01 2017-10-10 Ferring Bv Compositions d'inhibiteur de trans-signalisation par l'il-6 sélectif
SI3226888T1 (sl) 2014-12-01 2021-08-31 Ferring B.V. Dajanje selektivnega zaviralca signalizacije IL-6-trans
SG11201705063VA (en) 2014-12-23 2017-07-28 Bristol Myers Squibb Co Antibodies to tigit
DK3268391T3 (da) 2015-03-09 2021-09-13 Argenx Bvba Fremgangsmåder til reduktion af serumniveauer af Fc-indeholdende midler ved anvendelse af FcRn-antagonister
BR112017021696A2 (pt) 2015-04-10 2018-07-10 Amgen Inc muteínas de interleucina-2 para a expansão de células t regulatórias
US9644032B2 (en) 2015-05-29 2017-05-09 Bristol-Myers Squibb Company Antibodies against OX40 and uses thereof
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
PL3328419T3 (pl) 2015-07-30 2021-12-27 Macrogenics, Inc. Cząsteczki wiążące pd-1 i sposoby ich zastosowania
UA126016C2 (uk) 2015-08-03 2022-08-03 Біовератів Терапеутікс Інк. Злитий білок фактора іх
EP3763378A1 (de) 2015-08-06 2021-01-13 President and Fellows of Harvard College Verbesserte mikrobenbindende moleküle und verwendungen davon
RU2731202C2 (ru) 2015-10-08 2020-08-31 Макродженикс, Инк. Комбинированная терапия для лечения рака
ES2926969T3 (es) 2015-11-19 2022-10-31 Bristol Myers Squibb Co Anticuerpos contra el receptor de factor de necrosis de tumor inducido por glucocorticoides (gitr) y usos de los mismos
KR102424513B1 (ko) 2015-12-14 2022-07-25 마크로제닉스, 인크. Pd-1 및 ctla-4과의 면역반응성을 가진 이중특이적 분자, 및 이것의 사용 방법
TW201730212A (zh) 2016-02-17 2017-09-01 宏觀基因股份有限公司 Ｒｏｒ１－結合分子及其使用方法
IL295230A (en) 2016-03-04 2022-10-01 Bristol Myers Squibb Co Combination therapy with anti-cd73 antibodies
WO2017161173A1 (en) 2016-03-16 2017-09-21 Merrimack Pharmaceuticals, Inc. Engineered trail for cancer therapy
MX2018012433A (es) 2016-04-15 2019-03-01 Macrogenics Inc Moleculas de union b7-h3 novedosas, conjugados anticuerpo-farmaco de los mismos y metodos de uso de los mismos.
AU2017264578A1 (en) 2016-05-09 2019-01-03 Bristol-Myers Squibb Company TL1A antibodies and uses thereof
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
UY37325A (es) 2016-07-14 2018-01-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Anticuerpos monoclonales que se enlazan a tim3 para estimular respuestas inmunitarias y composiciones que los contienen
PL3484911T3 (pl) 2016-07-15 2021-03-08 F. Hoffmann-La Roche Ag Sposób oczyszczania PEGylowanej erytropoetyny
MX2019001503A (es) 2016-08-12 2019-06-03 Merck Patent Gmbh Tratamiento conjunto contra el cancer.
US10981976B2 (en) 2016-08-31 2021-04-20 University Of Rochester Human monoclonal antibodies to human endogenous retrovirus K envelope (HERV-K) and use thereof
EP3534947A1 (de) 2016-11-03 2019-09-11 Kymab Limited Antikörper, kombinationen mit antikörpern, biomarker, verwendungen und verfahren
BR112019010349A2 (pt) 2016-11-23 2019-10-08 Bioverativ Therapeutics Inc Anticorpos anti-fixa, anti-fxz e antifxa, molécula biespecífica, ácido nulceico, composiçãofarmacêutica e uso dos anteriores
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CN110267685B (zh) 2016-12-23 2023-06-20 伊缪诺金公司 靶向adam9的免疫缀合物及其使用方法
AR110424A1 (es) 2016-12-23 2019-03-27 Macrogenics Inc Moléculas de unión a adam9 y métodos de uso de las mismas
US20180230218A1 (en) 2017-01-04 2018-08-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
KR102573778B1 (ko) 2017-02-17 2023-08-31 브리스톨-마이어스 스큅 컴퍼니 알파-시뉴클레인에 대한 항체 및 그의 용도
CN110325209A (zh) 2017-02-24 2019-10-11 宏观基因有限公司 能够结合cd137和肿瘤抗原的双特异性结合分子及其用途
WO2018175403A1 (en) * 2017-03-20 2018-09-27 Bio-Techne Corporation Il-37 fusion protein and methods of making and using same
WO2018213097A1 (en) 2017-05-15 2018-11-22 University Of Rochester Broadly neutralizing anti-influenza monoclonal antibody and uses thereof
MX2019013132A (es) 2017-05-25 2020-01-27 Bristol Myers Squibb Co Anticuerpos que comprenden regiones constantes pesadas modificadas.
EP3694552A1 (de) 2017-10-10 2020-08-19 Tilos Therapeutics, Inc. Anti-lap-antikörper und verwendungen davon
JP7438106B2 (ja) 2017-10-14 2024-02-26 シートムエックス セラピューティクス，インコーポレイテッド 抗体、活性化可能抗体、二重特異性抗体、および二重特異性活性化可能抗体ならびにその使用方法
KR20200086722A (ko) 2017-11-21 2020-07-17 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 인터루킨-2의 부분 효능제
JP7422659B2 (ja) 2017-12-08 2024-01-26 アルジェニクス ビーブイ 全身型重症筋無力症治療のためのＦｃＲｎアンタゴニストの使用
MX2020006155A (es) 2017-12-12 2020-08-13 Macrogenics Inc Moleculas de union a cd-16 biespecificas y su uso en el tratamiento de enfermedades.
JP2021506291A (ja) 2017-12-19 2021-02-22 ゼンコア インコーポレイテッド 改変されたｉｌ−２ ｆｃ融合タンパク質
US11802154B2 (en) 2017-12-20 2023-10-31 Alexion Pharmaceuticals, Inc. Humanized anti-CD200 antibodies and uses thereof
US20210087267A1 (en) 2017-12-20 2021-03-25 Alexion Pharmaceuticals, Inc. Liquid formulations of anti-cd200 antibodies
JP7358361B2 (ja) 2018-01-12 2023-10-10 ブリストル－マイヤーズ スクイブ カンパニー Ｔｉｍ３に対する抗体およびその使用
US11685781B2 (en) 2018-02-15 2023-06-27 Macrogenics, Inc. Variant CD3-binding domains and their use in combination therapies for the treatment of disease
WO2019183040A1 (en) 2018-03-21 2019-09-26 Five Prime Therapeutics, Inc. ANTIBODIES BINDING TO VISTA AT ACIDIC pH
TW202003565A (zh) 2018-03-23 2020-01-16 美商必治妥美雅史谷比公司 抗mica及/或micb抗體及其用途
MX2020010204A (es) 2018-04-02 2021-01-29 Bristol Myers Squibb Co Anticuerpos anti-trem-1 y usos de los mismos.
CA3096703A1 (en) 2018-05-03 2019-11-07 University Of Rochester Anti-influenza neuraminidase monoclonal antibodies and uses thereof
TW202015723A (zh) 2018-05-18 2020-05-01 美商百歐維拉提夫治療公司 治療ａ型血友病的方法
EP3814378A1 (de) 2018-06-26 2021-05-05 ImmunoGen, Inc. Auf adam9 gerichtete immunokonjugate und verfahren zur verwendung davon
TW202428604A (zh) 2018-07-09 2024-07-16 美商戊瑞治療有限公司 結合至ilt4的抗體
WO2020014306A1 (en) 2018-07-10 2020-01-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
CN112638948A (zh) 2018-07-11 2021-04-09 戊瑞治疗有限公司 在酸性pH下结合至VISTA的抗体
SG11202103192RA (en) 2018-10-03 2021-04-29 Xencor Inc Il-12 heterodimeric fc-fusion proteins
US11130802B2 (en) 2018-10-10 2021-09-28 Tilos Therapeutics, Inc. Anti-lap antibody variants
TW202029980A (zh) 2018-10-26 2020-08-16 美商免疫遺傳股份有限公司 Ｅ ｐ Ｃ Ａ Ｍ 抗體、可活化抗體及免疫偶聯物以及其用途
JP2022505923A (ja) 2018-11-01 2022-01-14 メルク パテント ゲーエムベーハー 抗ｔｉｍ－３抗体を投与する方法
AU2019371457A1 (en) 2018-11-01 2021-05-20 Merck Patent Gmbh Anti-TIM-3 antibodies
JP2022513653A (ja) 2018-11-28 2022-02-09 ブリストル－マイヤーズ スクイブ カンパニー 修飾された重鎖定常領域を含む抗体
WO2020118011A1 (en) 2018-12-06 2020-06-11 Alexion Pharmaceuticals, Inc. Anti-alk2 antibodies and uses thereof
CN116063513A (zh) 2018-12-21 2023-05-05 Ose免疫疗法公司 人源化的抗人pd-1抗体
JP2022514698A (ja) 2018-12-21 2022-02-14 オーエスイー・イミュノセラピューティクス 二機能性抗ｐｄ－１／ｓｉｒｐａ分子
CN113614109A (zh) 2018-12-21 2021-11-05 Ose免疫疗法公司 双功能抗pd-1/il-7分子
US20220025050A1 (en) 2018-12-21 2022-01-27 Ose Immunotherapeutics Bifunctional molecule directed against human pd-1
WO2020154293A1 (en) 2019-01-22 2020-07-30 Bristol-Myers Squibb Company Antibodies against il-7r alpha subunit and uses thereof
WO2020165374A1 (en) 2019-02-14 2020-08-20 Ose Immunotherapeutics Bifunctional molecule comprising il-15ra
CN113811549A (zh) 2019-02-21 2021-12-17 Xencor股份有限公司 非靶向和靶向性il-10 fc融合蛋白
GB2589049C (en) 2019-04-11 2024-02-21 argenx BV Anti-IgE antibodies
EP3969119A1 (de) 2019-05-17 2022-03-23 Xencor, Inc. Il-7-fc-fusionsproteine
US11591388B2 (en) 2019-06-07 2023-02-28 argenx BV Pharmaceutical formulations of FcRn inhibitors suitable for subcutaneous administration
WO2021011678A1 (en) 2019-07-15 2021-01-21 Bristol-Myers Squibb Company Anti-trem-1 antibodies and uses thereof
WO2021011681A1 (en) 2019-07-15 2021-01-21 Bristol-Myers Squibb Company Antibodies against human trem-1 and uses thereof
CA3149719A1 (en) 2019-09-19 2021-03-25 Bristol-Myers Squibb Company Antibodies binding to vista at acidic ph
CA3157024A1 (en) 2019-10-03 2021-04-08 Xencor, Inc. Targeted il-12 heterodimeric fc-fusion proteins
WO2021122866A1 (en) 2019-12-17 2021-06-24 Ose Immunotherapeutics Bifunctional molecules comprising an il-7 variant
EP4087875B1 (de) 2020-01-08 2024-08-28 Argenx BV Antagonisten des humanen neonatalen fc rezeptors (fcrn) zur behandlung von pemphigus-erkrankungen
CA3162406A1 (en) 2020-01-10 2021-07-15 Vijaya Raghavan PATTABIRAMAN Modified il-2 polypeptides and uses thereof
KR102653906B1 (ko) 2020-01-14 2024-04-03 신테카인, 인크. 편향된 il2 뮤테인 방법 및 조성물
US20230107644A1 (en) 2020-04-01 2023-04-06 University Of Rochester Monoclonal antibodies against the hemagglutinin (ha) and neuraminidase (na) of influenza h3n2 viruses
EP4132971A1 (de) 2020-04-09 2023-02-15 Merck Sharp & Dohme LLC Affinitätsgereifte anti-lap-antikörper und verwendungen davon
MX2021015024A (es) 2020-04-28 2022-01-18 Univ Rockefeller Anticuerpos anti-sars-cov-2 ampliamente neutralizantes y métodos de uso de los mismos.
US20230192867A1 (en) 2020-05-15 2023-06-22 Bristol-Myers Squibb Company Antibodies to garp
WO2022010798A1 (en) 2020-07-06 2022-01-13 Kiromic BioPharma, Inc. Mesothelin isoform binding molecules and chimeric pd1 receptor molecules, cells containing the same and uses thereof
TW202406932A (zh) 2020-10-22 2024-02-16 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
TW202227481A (zh) 2020-11-04 2022-07-16 美國洛克菲勒大學 中和抗sars-cov-2抗體
WO2022108627A1 (en) 2020-11-18 2022-05-27 Kiromic Biopharma, Inc.Kiromic Biopharma, Inc. Gamma-delta t cell manufacturing processes and chimeric pd1 receptor molecules
WO2022129512A1 (en) 2020-12-17 2022-06-23 Ose Immunotherapeutics Bifunctional anti-pd1/il-7 molecules
AU2021399453A1 (en) 2020-12-18 2023-07-27 Zhuhai Trinomab Pharmaceutical Co., Ltd. Respiratory syncytial virus-specific binding molecule
US12060411B2 (en) 2021-01-15 2024-08-13 The Rockefeller University Neutralizing anti-SARS-CoV-2 antibodies
WO2022212876A1 (en) 2021-04-02 2022-10-06 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
AU2022253351A1 (en) 2021-04-09 2023-10-12 Ose Immunotherapeutics New scaffold for bifunctional molecules with improved properties
WO2022214652A1 (en) 2021-04-09 2022-10-13 Ose Immunotherapeutics Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains
US20240158537A1 (en) * 2021-07-09 2024-05-16 Bright Peak Therapeutics Ag Synthetic il-7 and il-7 immunocytokines
AU2022306145A1 (en) * 2021-07-09 2024-02-01 Bright Peak Therapeutics Ag Antibody conjugates and manufacture thereof
WO2023147399A1 (en) 2022-01-27 2023-08-03 The Rockefeller University Broadly neutralizing anti-sars-cov-2 antibodies targeting the n-terminal domain of the spike protein and methods of use thereof
WO2023242371A1 (en) 2022-06-15 2023-12-21 argenx BV Ph-dependent hsa-binding molecules and methods of use
WO2024015830A1 (en) 2022-07-12 2024-01-18 Cytomx Therapeutics, Inc. Epcam immunoconjugates and uses thereof
US20240228664A9 (en) 2022-07-22 2024-07-11 Bristol-Myers Squibb Company Antibodies Binding to Human PAD4 and Uses Thereof
WO2024028386A1 (en) 2022-08-02 2024-02-08 Ose Immunotherapeutics Multifunctional molecule directed against cd28
WO2024186635A2 (en) 2023-03-03 2024-09-12 Celldex Therapeutics, Inc. Anti-stem cell factor (scf) and anti-thymic stromal lymphopoietin (tslp) antibodies and bispecific constructs
WO2024200573A1 (en) 2023-03-27 2024-10-03 LAVA Therapeutics N.V. Nectin-4 binding agents and methods of use

Family Cites Families (173)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4469797A (en) 1982-09-23 1984-09-04 Miles Laboratories, Inc. Digoxigenin immunogens, antibodies, labeled conjugates, and related derivatives
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4966843A (en) 1982-11-01 1990-10-30 Cetus Corporation Expression of interferon genes in Chinese hamster ovary cells
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
KR850004274A (ko) 1983-12-13 1985-07-11 원본미기재 에리트로포이에틴의 제조방법
NZ210501A (en) 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
US4703008A (en) 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
US5082658A (en) 1984-01-16 1992-01-21 Genentech, Inc. Gamma interferon-interleukin-2 synergism
EP0158198A1 (de) 1984-03-29 1985-10-16 Takeda Chemical Industries, Ltd. DNA und ihre Verwendung
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4667016A (en) 1985-06-20 1987-05-19 Kirin-Amgen, Inc. Erythropoietin purification
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US5679543A (en) 1985-08-29 1997-10-21 Genencor International, Inc. DNA sequences, vectors and fusion polypeptides to increase secretion of desired polypeptides from filamentous fungi
US5643565A (en) 1985-09-20 1997-07-01 Chiron Corporation Human IL-2 as a vaccine adjuvant
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5359035A (en) 1985-12-21 1994-10-25 Hoechst Aktiengesellschaft Bifunctional proteins including interleukin-2 (IL-2) and granuloctyte macrophage colony stimulating factor (GM-CSF)
DE3712985A1 (de) 1987-04-16 1988-11-03 Hoechst Ag Bifunktionelle proteine
EP0237019A3 (de) 1986-03-14 1988-03-09 Toray Industries, Inc. Konjugiertes Interferon und dessen Herstellung unter Verwendung eines rekombinanten Gens
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
DK173067B1 (da) 1986-06-27 1999-12-13 Univ Washington Humant erythropoietin-gen, fremgangsmåde til ekspression deraf i transficerede cellelinier, de transficerede cellelinier sa
US4894227A (en) 1986-08-01 1990-01-16 Cetus Corporation Composition of immunotoxins with interleukin-2
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5508031A (en) 1986-11-21 1996-04-16 Cetus Oncology Corporation Method for treating biological damage using a free-radial scavenger and interleukin-2
US4732683A (en) 1986-12-02 1988-03-22 Biospectrum, Inc. Purification method for alpha interferon
US5019368A (en) 1989-02-23 1991-05-28 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
DE3856559T2 (de) 1987-05-21 2004-04-29 Micromet Ag Multifunktionelle Proteine mit vorbestimmter Zielsetzung
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
ATE122238T1 (de) 1987-06-10 1995-05-15 Dana Farber Cancer Inst Inc Bifunktionelle antikörperkonstruktionen und verfahren zur selektiven tötung von zellbeständen.
US5064646A (en) 1988-08-02 1991-11-12 The University Of Maryland Novel infectious bursal disease virus
DE3880766D1 (de) 1987-09-02 1993-06-09 Ciba Geigy Ag Konjugate von interferon alpha mit immunglobulinen.
ATE108068T1 (de) 1987-09-23 1994-07-15 Bristol Myers Squibb Co Antikörper-heterokonjugate zur töting von hiv- infizierten zellen.
PT88641B (pt) 1987-10-02 1993-04-30 Genentech Inc Metodo para a preparacao de uma variante de adesao
AU2635088A (en) 1987-12-04 1989-06-08 Du Pont Merck Pharmaceutical Company, The Immobilized interleukin 2 and interleukin 2 containing a carboxyl-terminal extension
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
CA1341588C (en) 1988-01-26 2009-01-06 Michel Revel Human ifn-beta2/i1-6, its purification and use
US5120525A (en) 1988-03-29 1992-06-09 Immunomedics, Inc. Radiolabeled antibody cytotoxic therapy of cancer
US4975369A (en) 1988-04-21 1990-12-04 Eli Lilly And Company Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen
IT1217724B (it) 1988-05-26 1990-03-30 Ist Naz Ric Sul Cancro Anticorpo monoclonale specifico per una sequenza di fibronettina espressa in cellule trasformate ibridoma secernente tale anticorpo e impiego dell'anticorpo monoclonale per la diagnosi di tumori
IE62463B1 (en) 1988-07-07 1995-02-08 Res Dev Foundation Immunoconjugates for cancer diagnosis and therapy
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
US5457038A (en) 1988-11-10 1995-10-10 Genetics Institute, Inc. Natural killer stimulatory factor
US5242824A (en) 1988-12-22 1993-09-07 Oncogen Monoclonal antibody to human carcinomas
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
ZA902949B (en) 1989-05-05 1992-02-26 Res Dev Foundation A novel antibody delivery system for biological response modifiers
US6750329B1 (en) * 1989-05-05 2004-06-15 Research Development Foundation Antibody delivery system for biological response modifiers
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
DE69019609T2 (de) 1989-07-07 1995-11-30 Takeda Chemical Industries Ltd Proteine und deren Herstellung.
US5073627A (en) 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
WO1991005867A1 (en) 1989-10-13 1991-05-02 Amgen Inc. Erythropoietin isoforms
US5856298A (en) 1989-10-13 1999-01-05 Amgen Inc. Erythropoietin isoforms
DK0790308T3 (da) 1989-12-22 2007-10-08 Hoffmann La Roche Cytoksisk lymfocytmodningsfaktor 35kD-underenhed samt monoklonale antistoffer rettet derimod
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
US7253264B1 (en) * 1990-06-28 2007-08-07 Sanofi-Arentideutschland GmbH Immunoglobulin fusion proteins, their production and use
US5650150A (en) * 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
US5709859A (en) 1991-01-24 1998-01-20 Bristol-Myers Squibb Company Mixed specificity fusion proteins
US6072039A (en) 1991-04-19 2000-06-06 Rohm And Haas Company Hybrid polypeptide comparing a biotinylated avidin binding polypeptide fused to a polypeptide of interest
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
US5199942A (en) 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
DE69227693T2 (de) 1991-08-30 1999-07-22 Fred Hutchinson Cancer Research Center, Seattle, Wash. Hybride cytokine
US20020037558A1 (en) * 1991-10-23 2002-03-28 Kin-Ming Lo E.coli produced immunoglobulin constructs
US6627615B1 (en) 1991-12-17 2003-09-30 The Regents Of The University Of California Methods and compositions for in vivo gene therapy
JP3649335B2 (ja) 1992-04-01 2005-05-18 ザ ロックフェラー ユニバーシティー 樹枝状細胞前駆体のインビトロ増殖の方法およびその免疫原製造への使用
ES2252732T3 (es) 1992-05-26 2006-05-16 Immunex Corporation Nueva citoquina que une cd30.
EP0646178A1 (de) 1992-06-04 1995-04-05 The Regents Of The University Of California Expression kassette mit im säugetier wirt funktionnellen regulator sequenzen
US5614184A (en) 1992-07-28 1997-03-25 New England Deaconess Hospital Recombinant human erythropoietin mutants and therapeutic methods employing them
EP0671926B1 (de) 1992-08-11 2002-11-13 President And Fellows Of Harvard College Immunmodulierende peptide
DE4228839A1 (de) 1992-08-29 1994-03-03 Behringwerke Ag Verfahren zum Nachweis und zur Bestimmung von Mediatoren
EP0627932B1 (de) 1992-11-04 2002-05-08 City Of Hope Antikörperkonstrukte
ATE342356T1 (de) 1992-11-05 2006-11-15 Sloan Kettering Inst Cancer Prostata-spezifisches membranantigen
US5738849A (en) 1992-11-24 1998-04-14 G. D. Searle & Co. Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them
US5543297A (en) 1992-12-22 1996-08-06 Merck Frosst Canada, Inc. Human cyclooxygenase-2 cDNA and assays for evaluating cyclooxygenase-2 activity
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US5738852A (en) 1993-04-20 1998-04-14 Solis Therapeutics, Inc. Methods of enhancing antigen-specific T cell responses
US5759551A (en) 1993-04-27 1998-06-02 United Biomedical, Inc. Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines
HUT73876A (en) 1993-04-29 1996-10-28 Abbott Lab Erythropoietin analog compositions and methods
US5554512A (en) 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
CA2125763C (en) 1993-07-02 2007-08-28 Maurice Kent Gately P40 homodimer of interleukin-12
IL110669A (en) 1993-08-17 2008-11-26 Kirin Amgen Inc Erythropoietin analogs
US5837682A (en) 1996-03-08 1998-11-17 The Children's Medical Center Corporation Angiostatin fragments and method of use
BR9507479A (pt) 1994-04-26 1997-09-16 Childrens Medical Center Angipstantina e processo de uso para inibição de angiogenese
US5639725A (en) 1994-04-26 1997-06-17 Children's Hospital Medical Center Corp. Angiostatin protein
CU22615A1 (es) 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US5888773A (en) 1994-08-17 1999-03-30 The United States Of America As Represented By The Department Of Health And Human Services Method of producing single-chain Fv molecules
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
ATE208633T1 (de) 1994-09-16 2001-11-15 Merck Patent Gmbh Immunokonjugate
EP0793504B1 (de) * 1994-12-12 2005-06-08 Beth Israel Deaconess Medical Center, Inc. Chimäre zytokine und ihre verwendung
US6485726B1 (en) 1995-01-17 2002-11-26 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6086875A (en) 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US5552524A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5691309A (en) 1995-01-31 1997-11-25 Eli Lilly And Company Anti-obesity proteins
US5891680A (en) 1995-02-08 1999-04-06 Whitehead Institute For Biomedical Research Bioactive fusion proteins comprising the p35 and p40 subunits of IL-12
WO1996028548A1 (en) 1995-03-10 1996-09-19 Genentech, Inc. Receptor activation by gas6
US5719266A (en) 1995-03-17 1998-02-17 Eli Lilly And Company Anti-obesity proteins
US6281010B1 (en) 1995-06-05 2001-08-28 The Trustees Of The University Of Pennsylvania Adenovirus gene therapy vehicle and cell line
GB9511935D0 (en) * 1995-06-13 1995-08-09 Smithkline Beecham Plc Novel compound
HUP9802609A2 (hu) 1995-06-30 1999-03-29 Eli Lilly And Co. A diabetes kezelésére szolgáló eljárás
US6406689B1 (en) 1995-10-03 2002-06-18 Frank W. Falkenberg Compositions and methods for treatment of tumors and metastatic diseases
US5854205A (en) 1995-10-23 1998-12-29 The Children's Medical Center Corporation Therapeutic antiangiogenic compositions and methods
US6080409A (en) 1995-12-28 2000-06-27 Dendreon Corporation Immunostimulatory method
US5723125A (en) * 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
US6750334B1 (en) * 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
CA2205757C (en) 1996-05-30 2006-01-24 F. Hoffmann-La Roche Ag Pyridazinone derivatives and their use as inhibitors of prostaglandin g/h synthase i and ii(cox i and ii)
US5922685A (en) 1996-06-05 1999-07-13 Powderject Vaccines, Inc. IL-12 gene therapy of tumors
ES2176574T3 (es) 1996-09-03 2002-12-01 Gsf Forschungszentrum Umwelt Utilizacion de anticuerpos bi y triespecificos para la induccion de inmunidad tumoral.
US5994104A (en) 1996-11-08 1999-11-30 Royal Free Hospital School Of Medicine Interleukin-12 fusion protein
US6100387A (en) * 1997-02-28 2000-08-08 Genetics Institute, Inc. Chimeric polypeptides containing chemokine domains
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
DK0973550T3 (da) 1997-04-11 2003-02-10 Searle & Co Antagonistiske anti-AVB3-integrin-antistoffer
ES2221717T3 (es) 1997-12-08 2005-01-01 Emd Lexigen Research Center Corp. Proteinas de fusion heterodimeras utiles para inmunoterapia dirigida e inmunoestimulacion general.
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
HUP0100813A3 (en) * 1998-02-25 2003-08-28 Lexigen Pharmaceuticals Corp L Enhancing the circulating half-life of antibody-based fusion proteins
JP2002511432A (ja) 1998-04-15 2002-04-16 レキシジェン ファーマシューティカルズ コーポレイション 新脈管形成インヒビターの同時投与による抗体−サイトカイン融合タンパク質媒介性免疫応答の増強
AU758851B2 (en) * 1998-04-17 2003-04-03 Lexigen Pharmaceuticals Corporation Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with prostaglandin inhibitor
US6284536B1 (en) 1998-04-20 2001-09-04 The Regents Of The University Of California Modified immunoglobin molecules and methods for use thereof
AU751823B2 (en) 1998-05-14 2002-08-29 Merck Patent Gmbh Fused protein
US6620382B1 (en) 1998-05-22 2003-09-16 Biopheresis Technologies, Llc. Method and compositions for treatment of cancers
AU770555B2 (en) 1998-08-17 2004-02-26 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
DE69942207D1 (de) * 1998-08-25 2010-05-12 Merck Patent Gmbh Expression und export von angiostatin und endostatin als immunofusins
US6646113B1 (en) * 1998-09-17 2003-11-11 The Trustees Of The University Of Pennsylvania Nucleic acid molecule encoding human survival of motor neuron-interacting protein 1 (SIP1) deletion mutants
US6335176B1 (en) 1998-10-16 2002-01-01 Pharmacopeia, Inc. Incorporation of phosphorylation sites
CA2356401A1 (en) * 1999-01-07 2000-07-13 Lexigen Pharmaceuticals, Corp. Expression and export of anti-obesity proteins as fc fusion proteins
EP1178785B1 (de) 1999-05-06 2008-12-24 Wake Forest University Zusammensetzungen und methoden zur identifikation von antigenen, die eine immunantwort hervorrufen
US6348192B1 (en) 1999-05-11 2002-02-19 Bayer Corporation Interleukin-2 mutein expressed from mammalian cells
CA2372400C (en) * 1999-05-19 2010-04-27 Lexigen Pharmaceuticals Corp. Expression and export of interferon-alpha proteins as fc fusion proteins
CZ299516B6 (cs) * 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
JO2291B1 (en) 1999-07-02 2005-09-12 اف . هوفمان لاروش ايه جي Erythropoietin derivatives
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
KR100827757B1 (ko) * 1999-08-09 2008-05-07 메르크 파텐트 게엠베하 복수의 시토킨-항체 복합체
JP2003514552A (ja) 1999-11-12 2003-04-22 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 改善された性質を有するエリトロポエチンの形態
US20050202538A1 (en) 1999-11-12 2005-09-15 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
ATE336514T1 (de) 2000-02-11 2006-09-15 Merck Patent Gmbh Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen
DK1719528T3 (da) * 2000-02-24 2012-01-09 Philogen Spa Sammensætninger og fremgangsmåder til behandling af angiogenese i patologiske læsioner
US6586398B1 (en) * 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
AU2001263149A1 (en) * 2000-05-12 2001-11-26 Neose Technologies, Inc. In vitro fucosylation recombinant glycopeptides
RU2272644C2 (ru) * 2000-06-29 2006-03-27 Мерк Патент Гмбх Усиление иммунной реакции, медиатором которой является слитый протеин антитело-цитокин, при помощи комбинированного лечения агентами, увеличивающими поглощение иммуноцитокина
EP1392826A2 (de) * 2001-01-18 2004-03-03 MERCK PATENT GmbH Bifunktionelle fusionsproteine mit glukocerebrosidase-aktivität
WO2002066514A2 (en) * 2001-02-19 2002-08-29 Merck Patent Gmbh Artificial fusion proteins with reduced immunogenicity
EP1366067B1 (de) 2001-03-07 2012-09-26 Merck Patent GmbH Verfahren zur expression von proteinen mit einer hybrid-isotyp-antikörpereinheit
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
AU2002308562B2 (en) 2001-05-03 2008-01-24 Merck Patent Gmbh Recombinant tumor specific antibody and use thereof
US6900292B2 (en) * 2001-08-17 2005-05-31 Lee-Hwei K. Sun Fc fusion proteins of human erythropoietin with increased biological activities
EP1454138B1 (de) 2001-12-04 2012-01-18 Merck Patent GmbH Immunocytokine mit modulierter selektivität
EP1487992A4 (de) 2002-03-15 2007-10-31 Brigham & Womens Hospital Verabreichung über die zentralen luftwege für die systemische zuführung von therapeutika
US7217798B2 (en) * 2003-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of Fc-fusion protein serum half-lives by mutagenesis
PL211180B1 (pl) 2002-12-17 2012-04-30 Merck Patent Gmbh Białko fuzyjne typu przeciwciało-IL2, wektor zawierający sekwencję kwasów nukleinowych kodujących takie białko, kompozycja farmaceutyczna zawierająca takie białko fuzyjne oraz jego zastosowania do wytwarzania leków
US20050069521A1 (en) 2003-08-28 2005-03-31 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of interleukin-2 proteins
DE602004013372T2 (de) 2003-12-30 2009-07-02 Merck Patent Gmbh Il-7-fusionsproteine mit antikörperportionen, deren herstellung und deren verwendung
JP2008504008A (ja) 2003-12-31 2008-02-14 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 改良された薬物動態を有するＦｃ−エリスロポエチン融合タンパク質
DE602005016773D1 (de) 2004-01-22 2009-11-05 Merck Patent Gmbh Antikrebs-antikörper mit reduzierter komplementfixierung
US7670595B2 (en) 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
KR20070085886A (ko) 2004-12-09 2007-08-27 메르크 파텐트 게엠베하 감소된 면역원성의 ｉｌ-7 변이체
US20070104689A1 (en) 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
WO2007076933A1 (en) 2005-12-30 2007-07-12 Merck Patent Gmbh Interleukin-12p40 variants with improved stability
EP2270050B1 (de) 2005-12-30 2013-06-05 Merck Patent GmbH Anti-C19 Antikörper mit reduzierter Immunogenizität
ES2382164T3 (es) 2005-12-30 2012-06-05 Merck Patent Gmbh Anticuerpos anti-IL-6 que impiden la unión de la IL-6 en complejo con el IL-6R( ) a la GP130
JP5474531B2 (ja) 2006-03-24 2014-04-16 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 操作されたヘテロ二量体タンパク質ドメイン
EP2038417A2 (de) 2006-07-06 2009-03-25 Merck Patent GmbH Zusammensetzungen und verfahren zur verstärkung der wirksamkeit von il-2-vermittelten immunreaktionen
US7622522B2 (en) 2007-09-27 2009-11-24 Sabic Innovative Plastics Ip B.V. Flame-retardant poly(arylene ether) composition and its use as a covering for coated wire

Also Published As

Publication number Publication date
HUP0204475A2 (en) 2003-04-28
JP5179689B2 (ja) 2013-04-10
CN1406249A (zh) 2003-03-26
CA2399832A1 (en) 2001-08-16
WO2001058957A2 (en) 2001-08-16
WO2001058957A3 (en) 2002-05-02
US7091321B2 (en) 2006-08-15
DE60122286T2 (de) 2007-08-02
JP5572665B2 (ja) 2014-08-13
EP1252192A2 (de) 2002-10-30
CN1406249B (zh) 2010-06-16
US20090264627A1 (en) 2009-10-22
US20020147311A1 (en) 2002-10-10
ES2269366T3 (es) 2007-04-01
AU4314801A (en) 2001-08-20
US20060034836A1 (en) 2006-02-16
US7507406B2 (en) 2009-03-24
JP2012176969A (ja) 2012-09-13
NO20023774L (no) 2002-08-09
EP1252192B1 (de) 2006-08-16
NO20023774D0 (no) 2002-08-09
US7790415B2 (en) 2010-09-07
DK1252192T3 (da) 2006-11-20
CA2399832C (en) 2011-09-20
PT1252192E (pt) 2007-01-31
MXPA02007733A (es) 2004-09-10
JP2003522200A (ja) 2003-07-22
CY1105725T1 (el) 2010-12-22
ATE336514T1 (de) 2006-09-15

Similar Documents

Publication Publication Date Title
DE60122286D1 (de) Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen
DK1088084T3 (da) Erythropoietin analog-humant serumalbumin fusionsprotein
EA200001023A1 (ru) Специфическое в отношении fapa-(протеин альфа активации фибробласта) антитело с повышенной продуктивностью
ATE490969T1 (de) Modifizierte transferrin-fusionsproteine
BR0208603A (pt) Marcadores de tumor para carcinoma de células renais
TR200002338T2 (tr) Stratejik olarak yenilenmiş hepatit B çekirdek proteinler.
BR0112111A (pt) Realce de respostas imunes mediadas por proteìna de fusão de anticorpo-citocina por tratamento combinado com agentes de realce de captação de imunocitocina
NO176575C (no) Sammensmeltet gen, kloningsvektor, samt anvendelse av kloningsvektoren
ES2113088T3 (es) Metodo de entrega de agentes a celulas diana.
DK0561890T3 (da) DNA ekspressionssystemer baseret på alphavira
ATE433491T1 (de) Oligomerische komplexe von chimären proteinen mit verbessertem immunogenen potential
ES2165851T3 (es) Proteinas multivalentes que se unen a antigenos.
GR3026658T3 (en) Hydrazino-type radionuclide chelators having an n 3?s configuration
DE69735854D1 (de) Polypeptide, die mit alfalfamosaikviralen oder ilarviralen kapsiden fusioniert sind
DE69417426D1 (de) N2s2-chelatoren des hydrazino-typs
DE3588006D1 (de) Atrielle natriumuretische/gefässerweiterende polypeptide.
DK0672063T3 (da) Mindste genkendelsesenhed af et PEM mucintandemgentagelsesspecifikt monoklonalt antistof
NO854460L (no) Syntetisk hepatitis-b-vaksine inbefattende baade t-celle og b-celledeterminanter.
GB9307371D0 (en) Fusion proteins
SE9403526D0 (sv) New Peptides
DE60330680D1 (de) Transferrin-fusionsproteinbibliotheken
DK218886D0 (da) Tvaerreaktive og beskyttende epitoper af circumsporozoit-proteiner
ATE356831T1 (de) Neuer galaninrezeptor
DE60027581D1 (de) Design von immunogene
ATE220409T1 (de) Rückgewinnung von proteinen durch fällung mit ligninsulfonate

Legal Events

Date Code Title Description
8364 No opposition during term of opposition